Bracket Has Been Acquired by Genstar Capital
March 30, 2017
Bracket, a leading scientifically-driven clinical trial technology and specialty services provider, and a portfolio company of Parthenon Capital Partners (“Parthenon”), has been acquired by Genstar Capital (“Genstar”).
Cain Brothers served as a co-advisor in connection with the transaction.
Founded in 2001, and headquartered in Wayne, PA, Bracket offers an integrated suite of complementary solutions that help pharmaceutical and biotechnology companies, as well as contract research organizations, maximize clinical data integrity and ultimately improve outcomes with clinical trials through leveraging core competencies in Science, Technology, and Service. Bracket has over 700 employees and provides services in more than 90 countries to a diverse base of global customers, including 15 of the top 20 biopharma companies. Bracket experienced strong growth under the management of Parthenon, a growth-oriented private equity firm dedicated to building leading companies in the healthcare and financial services industries.
Genstar is a San Francisco based, leading private equity firm that has been actively investing in high quality companies for more than 25 years. Genstar manages funds with total capital commitments of approximately $9 billion and targets investments in the healthcare, financial services, software, and industrial technology industries.